Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Metabolic, and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FOXO1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FOXO1 Wild Type & Phosphorylation-Resistant Mutant Proteins High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View FOXO1 Products |
| Gene Delivery | FOXO1 Promise-ORF / Lentivirus Full-length ORF and mutant variants for stable cell line generation. |
View FOXO1 Products |
| Benchmark Ab | Anti-FOXO1 Recombinant Positive Control Sequence-verified sequence for assay validation. |
View FOXO1 Products |
| Validator | FOXO1 siRNA Set For target knockdown and specificity verification. |
View FOXO1 Products |
| Related Target A | AKT1 (Protein Kinase B) Primary upstream kinase phosphorylating FOXO1 at Thr24, Ser256, and Ser319. |
View AKT1 Products |
| Related Target B | PTEN Key upstream negative regulator of the PI3K/AKT/FOXO1 pathway. |
View PTEN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phosphorylation-dependent translocation assays | Phospho-resistant (T24A/S256A/S319A) mutant proteins and lentiviruses available. |
| DNA-binding domain (DBD) specificity | High-purity recombinant FOXO1 DBD proteins verified by mass spectrometry. |
| Lack of reliable positive controls | Clinical-grade benchmark antibodies included in the portfolio. |
| Off-target validation in cellular models | Highly specific siRNA sets verified for target gene knockdown. |
Live FOXO1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FOXO1 therapeutics is intensifying, with major players shifting focus from broad-spectrum kinase inhibitors to direct transcription factor modulation, including small-molecule inhibitors, activators, and PROTAC-mediated degraders. As first-generation therapies targeting upstream nodes (like AKT and PI3K) face dose-limiting toxicities and resistance, the next wave of R&D is targeting direct FOXO1 modulation to selectively reprogram metabolic pathways and restore immune cell fitness in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Bayer, Academic Consortia | Oncology (Prostate Cancer, B-cell Lymphomas) | Selectivity assays using WT vs. mutant FOXO1 proteins. |
| PROTAC Degraders | Biotech Startups, Arvinas | Refractory Solid Tumors, Hematological Malignancies | Ubiquitination and degradation assays requiring high-purity recombinant target. |
| Small Molecule Activators | Metabolic-focused Biopharma | Type 2 Diabetes, NAFLD/NASH | Nuclear translocation and DNA-binding assays utilizing lentiviral reporters. |